BofA sees 'attractive entry point' in Kenvue after Tylenol controversy

Health

Bofa Sees 'Attractive Entry Point' In Kenvue After Tylenol Controversy

By CNBC

Bank of America is sticking by Kenvue and views its most recent sell-off as a buying opportunity for investors. Analyst Anna Lizzul reiterated her buy rating and $25 price target on the stock in a note to clients, reaffirming her expectation that the ...Read more

Related Posts

Senator: Trump administration plans to remove 700 Guatemalan children

Senator: Trump administration plans to remove 700 Guatemalan children

Aug 29, 2025
RFK Jr. testifies before Senate Finance Committee amid CDC turmoil, vaccine changes

RFK Jr. testifies before Senate Finance Committee amid CDC turmoil, vaccine changes

Sep 04, 2025
Painkillers taken by millions every day may be silently supercharging one of the world's deadliest health crises

Painkillers taken by millions every day may be silently supercharging one of the world's deadliest health crises

Aug 29, 2025
Rwanda says 7 deportees arrived from the US in August under agreement with Washington

Rwanda says 7 deportees arrived from the US in August under agreement with Washington

Aug 28, 2025
We use cookies to help provide you with the best experience when you visit our websites. By using this site you consent to the use of cookies on your device. see our cookie policy.